Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study.
Tingting FengQian LiRui ZhuChang YuLiwei XuLisha YingCanming WangWeiming XuJinchao WangJing ZhuMinran HuangChenyang XuJiaoyue JinXiaotian ZhangTingting LuYing YangChangbin ZhuQixun ChenDan SuPublished in: Journal for immunotherapy of cancer (2024)
The NCIRPs model that was developed and validated using treatment-naïve endoscopic samples from the largest ESCC neoadjuvant chemoimmunotherapy dataset represents a robust and clinically meaningful approach to select a putative responder for neoadjuvant chemoimmunotherapy in locally advanced ESCC patients.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- phase ii study
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- lymph node
- peritoneal dialysis
- open label
- prognostic factors
- clinical trial
- randomized controlled trial
- ultrasound guided
- combination therapy